Literature DB >> 6282986

Effect of acyclovir on genital herpes in guinea pigs.

A D Pronovost, H L Lucia, P R Dann, G D Hsiung.   

Abstract

The chemotherapeutic efficacy of acyclovir was evaluated in guniea pigs that were inoculated intravaginally with herpes simplex virus type 2 (HSV-2). Acyclovir was administered systemically (50 mg/kg of body weight per day ip) beginning three days after inoculation and continuing for 10-11 days. Treatment with acyclovir reduced the incidence of paralysis of the hind limbs, mortality, and the severity and duration of genital lesions but had little effect on the excretion of virus from the genital tract. Recovery of HSV-2 from neural tissues of infected animals during latent infection was less frequent in acyclovir-treated animals than in untreated ones. These data suggest that acyclovir may be a promising drug for altering the severity of clinical genital herpes in humans during acute infection and reducing the incidence of viral latency following primary infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6282986     DOI: 10.1093/infdis/145.6.904

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Evaluation of a novel, anti-herpes simplex virus compound, acyclovir elaidate (P-4010), in the female guinea pig model of genital herpes.

Authors:  R Jennings; T L Smith; F Myhren; J Phillips; M L Sandvold
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Antiviral activity of 5-ethyl-2'-deoxyuridine against herpes simplex viruses in cell culture, mice, and guinea pigs.

Authors:  R F Schinazi; R T Scott; J Peters; V Rice; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs.

Authors:  E B Fraser-Smith; D F Smee; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

4.  Activity of (+)-cyclaradine (Sch 31172) against herpes simplex virus in vitro and in vivo.

Authors:  J Schwartz; M Ostrander; N J Butkiewicz; M Lieberman; C Lin; J Lim; G H Miller
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

5.  Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.

Authors:  M N Ellis; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

6.  Efficacy of the acyclic guanosine analog buciclovir [(R)-9-(3,4-dihydroxybutyl)guanine] in experimental genital herpes.

Authors:  B Lundgren; A C Ericson; M Berg; R Datema
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

7.  Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.

Authors:  Kiyomitsu Katsumata; Koji Chono; Kenji Sudo; Yasuaki Shimizu; Toru Kontani; Hiroshi Suzuki
Journal:  Molecules       Date:  2011-08-25       Impact factor: 4.411

8.  Mysteries and miracles: personal recollections in clinical and diagnostic virology.

Authors:  G D Hsiung
Journal:  Clin Diagn Virol       Date:  1995-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.